Evidence map›Paper›PMID 39195218›Full record

ArticleCells2024

Cytokeratin 18 as a Novel Biomarker in Patients with Hypertrophic Cardiomyopathy.

Konstantinos Fragkiadakis, Niki Ktena, Aikaterini Kalantidou, Eirini Dermitzaki, Ioannis Anastasiou, Stamatis Papathanassiou, Joanna Kontaraki, Petros Kalomoirakis, Emmanuel Kanoupakis, Alexandros Patrianakos and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Konstantinos FragkiadakisCardiology Department, Heraklion University General Hospital, 71110 Heraklion, Greece.ORCID 0000-0002-5342-5411
Niki KtenaDivision of Basic Sciences, School of Medicine, University of Crete, 71003 Heraklion, Greece.ORCID 0000-0001-8308-3646
Aikaterini KalantidouClinical Chemistry, School of Medicine, University of Crete, 71003 Heraklion, Greece.
Eirini DermitzakiClinical Chemistry, School of Medicine, University of Crete, 71003 Heraklion, Greece.
Ioannis AnastasiouCardiology Department, Heraklion University General Hospital, 71110 Heraklion, Greece.
Stamatis PapathanassiouInstitute of Molecular Biology, 55128 Mainz, Germany.
Joanna KontarakiCardiology Department, School of Medicine, University of Crete, 71003 Heraklion, Greece.ORCID 0000-0003-3160-1856
Petros KalomoirakisCardiology Department, Heraklion University General Hospital, 71110 Heraklion, Greece.
Emmanuel KanoupakisCardiology Department, Heraklion University General Hospital, 71110 Heraklion, Greece.
Alexandros PatrianakosCardiology Department, Heraklion University General Hospital, 71110 Heraklion, Greece.ORCID 0000-0001-7916-1664
Antonis PapadomanolakisForensic Medicine Unit, Department of Forensic Sciences, School of Medicine, University of Crete, 71003 Heraklion, Greece.
Efsevia DaskalakiForensic Medicine Unit, Department of Forensic Sciences, School of Medicine, University of Crete, 71003 Heraklion, Greece.
Theodora KiousiForensic Medicine Unit, Department of Forensic Sciences, School of Medicine, University of Crete, 71003 Heraklion, Greece.
Katerina KourakiLaboratory of Pathology, University General Hospital of Heraklion, 71110 Heraklion, Greece.
Elena KraniotiForensic Medicine Unit, Department of Forensic Sciences, School of Medicine, University of Crete, 71003 Heraklion, Greece.ORCID 0000-0002-1627-5899
Maria TzardiLaboratory of Pathology, University General Hospital of Heraklion, 71110 Heraklion, Greece.
Maria VenihakiClinical Chemistry, School of Medicine, University of Crete, 71003 Heraklion, Greece.ORCID 0000-0002-3789-8032
Domna KaragogeosDivision of Basic Sciences, School of Medicine, University of Crete, 71003 Heraklion, Greece.
Yassemi CapetanakiCenter of Basic Research, Biomedical Research Foundation, Academy of Athens, 11527 Athens, Greece.ORCID 0000-0002-3089-0767
Dimitris KardassisLaboratory of Biochemistry, School of Medicine, University of Crete, 71003 Heraklion, Greece.
Georgios KochiadakisCardiology Department, Heraklion University General Hospital, 71110 Heraklion, Greece.
Fragkiskos ParthenakisCardiology Department, Heraklion University General Hospital, 71110 Heraklion, Greece.
Maria MarketouCardiology Department, Heraklion University General Hospital, 71110 Heraklion, Greece.ORCID 0000-0003-1888-3430

Funding

Hellenic Cardiological Society 17-07-2017
6 · The paper itself

Abstract

Hypertrophic cardiomyopathy (HCM) is a heart muscle disease associated with an increased risk for sudden cardiac death (SCD). Cytokeratin 18-based proteins, such as M30 and M65 antigens, are known cell-death biomarkers. M30 antigen is released from cells during apoptosis, and M65 antigen is released during cell death from any cause, such as apoptosis or necrosis. We aimed to study the expression of M30 and M65 antigens in peripheral blood obtained by 46 HCM patients and compare with 27 age- and sex-matched patients without HCM. We also investigated the CK18 expression in myocardium from postmortem HCM hearts. M30 and M65 antigens were significantly increased in the HCM vs. non-HCM group (Μ30: 338 ± 197 U/uL vs. 206 ± 166 U/uL,

Indexed as

BiomarkersCardiomyopathy, HypertrophicKeratin-18AdultAgedApoptosisDeath, Sudden, CardiacFemaleHumansMaleMiddle AgedMyocardiumNecrosisPeptide FragmentsBiomarkersKeratin-18M65 antigen, humanPeptide Fragmentsbiomarkerscell deathcytokeratin-18hypertrophic cardiomyopathyM30 antigenM65 antigen

Identifiers

PMID39195218
PMCPMC11352956

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.